Adherence Monitoring System in Managing Myelosuppression in Patients With Newly Diagnosed Malignant Gliomas Receiving Temozolomide and Radiation Therapy

PRIMARY OBJECTIVES:

I. To develop an adherence monitoring system within Epic that is functionally equivalent to
the previously designed and validated system in the Cancer Center Oncology Research
Information System (ORIS) for patients with newly diagnosed malignant gliomas receiving
concurrent temozolomide and radiation therapy.

II. To test the newly designed Epic system by comparing the frequency and timing of flags
(laboratory date flags, visit date flags and in-patient status flags) and non-adherent days
generated with the frequency and timing of those generated by ORIS for patients with newly
diagnosed malignant gliomas receiving concurrent temozolomide and radiation therapy.

SECONDARY OBJECTIVES:

I. To develop both systems so that they may be easily adapted in the future to other
therapies that require compliance monitoring.

OUTLINE:

Patient lab and visit dates are monitored by the Cancer Center ORIS and EPIC based systems
during the 42 days of the concurrent temozolomide and radiation therapy.

Inclusion Criteria:

- All patients who receive concurrent temozolomide and radiation therapy for newly
diagnosed malignant gliomas during and after the construction of the system until the
end of the study

Exclusion Criteria:

- Patients participating in clinical trials or other deviations from standard therapies
that engender similar monitoring risk will be evaluated for this study on a case by
case basis